Unlocking Bevacizumab's Potential

Background: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent gliobl...

Descripción completa

Detalles Bibliográficos
Autores: Álvarez-Torres, María del Mar, Balañá, Carmen|||0000-0003-0771-0390, Fuster-Garcia, Elies|||0000-0002-0716-8960, Puig, Josep|||0000-0003-2791-6599, García Gómez, Juan Miguel|||0000-0002-3851-1557
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:302170
Acceso en línea:https://ddd.uab.cat/record/302170
https://dx.doi.org/urn:doi:10.3390/cancers16010161
Access Level:acceso abierto
Palabra clave:Glioblastoma
Predictive biomarker
Angiogenesis
Bevacizumab
Rcbv
id ES_ceac33bf769e72e042fe04041c6d35d8
oai_identifier_str oai:ddd.uab.cat:302170
network_acronym_str ES
network_name_str España
repository_id_str
spelling Unlocking Bevacizumab's PotentialrCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype PatientsÁlvarez-Torres, María del MarBalañá, Carmen|||0000-0003-0771-0390Fuster-Garcia, Elies|||0000-0002-0716-8960Puig, Josep|||0000-0003-2791-6599García Gómez, Juan Miguel|||0000-0002-3851-1557GlioblastomaPredictive biomarkerAngiogenesisBevacizumabRcbvBackground: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent glioblastomas remains a subject of debate, as it does not universally improve patient survival. Purposes: In this study, we aimed to analyze the influence of tumor vascularity on the benefit provided by BVZ and propose preoperative rCBVmax at the high angiogenic tumor habitat as a predictive biomarker to select patients who can benefit the most. Methods: Clinical and MRI data from 106 patients with glioblastoma IDH-wildtype have been analyzed. Thirty-nine of them received BVZ, and the remaining sixty-seven did not receive a second-line treatment. The ONCOhabitats method was used to automatically calculate rCBV. Results: We found a median survival from progression of 305 days longer for patients with moderate vascular tumors who received BVZ than those who did not receive any second-line treatment. This contrasts with patients with high-vascular tumors who only presented a median survival of 173 days longer when receiving BVZ. Furthermore, better responses to BVZ were found for the moderate-vascular group with a higher proportion of patients alive at 6, 12, 18, and 24 months after progression. Conclusions: We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7.5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment. 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/302170https://dx.doi.org/urn:doi:10.3390/cancers16010161reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengAgencia Estatal de Investigación https://doi.org/10.13039/501100011033 PID2019-104978RB-I00Agencia Estatal de Investigación https://doi.org/10.13039/501100011033 PID2021-127110OA-I00Fundació la Marató de TV3 https://doi.org/10.13039/100008666 665/C/2013open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3021702026-06-06T12:50:31Z
dc.title.none.fl_str_mv Unlocking Bevacizumab's Potential
rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients
title Unlocking Bevacizumab's Potential
spellingShingle Unlocking Bevacizumab's Potential
Álvarez-Torres, María del Mar
Glioblastoma
Predictive biomarker
Angiogenesis
Bevacizumab
Rcbv
title_short Unlocking Bevacizumab's Potential
title_full Unlocking Bevacizumab's Potential
title_fullStr Unlocking Bevacizumab's Potential
title_full_unstemmed Unlocking Bevacizumab's Potential
title_sort Unlocking Bevacizumab's Potential
dc.creator.none.fl_str_mv Álvarez-Torres, María del Mar
Balañá, Carmen|||0000-0003-0771-0390
Fuster-Garcia, Elies|||0000-0002-0716-8960
Puig, Josep|||0000-0003-2791-6599
García Gómez, Juan Miguel|||0000-0002-3851-1557
author Álvarez-Torres, María del Mar
author_facet Álvarez-Torres, María del Mar
Balañá, Carmen|||0000-0003-0771-0390
Fuster-Garcia, Elies|||0000-0002-0716-8960
Puig, Josep|||0000-0003-2791-6599
García Gómez, Juan Miguel|||0000-0002-3851-1557
author_role author
author2 Balañá, Carmen|||0000-0003-0771-0390
Fuster-Garcia, Elies|||0000-0002-0716-8960
Puig, Josep|||0000-0003-2791-6599
García Gómez, Juan Miguel|||0000-0002-3851-1557
author2_role author
author
author
author
dc.subject.none.fl_str_mv Glioblastoma
Predictive biomarker
Angiogenesis
Bevacizumab
Rcbv
topic Glioblastoma
Predictive biomarker
Angiogenesis
Bevacizumab
Rcbv
description Background: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent glioblastomas remains a subject of debate, as it does not universally improve patient survival. Purposes: In this study, we aimed to analyze the influence of tumor vascularity on the benefit provided by BVZ and propose preoperative rCBVmax at the high angiogenic tumor habitat as a predictive biomarker to select patients who can benefit the most. Methods: Clinical and MRI data from 106 patients with glioblastoma IDH-wildtype have been analyzed. Thirty-nine of them received BVZ, and the remaining sixty-seven did not receive a second-line treatment. The ONCOhabitats method was used to automatically calculate rCBV. Results: We found a median survival from progression of 305 days longer for patients with moderate vascular tumors who received BVZ than those who did not receive any second-line treatment. This contrasts with patients with high-vascular tumors who only presented a median survival of 173 days longer when receiving BVZ. Furthermore, better responses to BVZ were found for the moderate-vascular group with a higher proportion of patients alive at 6, 12, 18, and 24 months after progression. Conclusions: We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7.5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/302170
https://dx.doi.org/urn:doi:10.3390/cancers16010161
url https://ddd.uab.cat/record/302170
https://dx.doi.org/urn:doi:10.3390/cancers16010161
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Agencia Estatal de Investigación https://doi.org/10.13039/501100011033 PID2019-104978RB-I00
Agencia Estatal de Investigación https://doi.org/10.13039/501100011033 PID2021-127110OA-I00
Fundació la Marató de TV3 https://doi.org/10.13039/100008666 665/C/2013
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420012578537472
score 15.811543

Similares en LA Referencia